Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner@exelixis.com Varant Shirvanian Director, Investor Relations Exelixis, Inc. 650-837-7917 vshirvanian@exelixis.com Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Total Revenues of $539.5 million, Cabozantinib Franchise U.S. Net Product Revenues of $478.1 million - - GAAP Diluted EPS of $0.40, Non-GAAP Diluted EPS of $0.47 - - Increasing Total Revenues and Net Product Revenue ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

The midcap biotech just became an even better buy.There is a loose relationship between price and quality on the stock market. Penny stocks are overwhelmingly regarded as high risk, while many larger-cap shares trade at high prices.Still, it's possible to find solid businesses whose share prices aren't too high -- perhaps following a recent stock split or because the market is ignoring their potential, or for some other reason. In other words, there is no need to break the bank to invest in quality companie ...

Exelixis (EXEL) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on October 29 ...

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE . I have embraced employing covered call holdings around most of my small and midcap biotech positions over the past five to six years. Option premiums around this high-beta part of ...

文章核心观点 - 该文章作者是一名资深的生物科技和医疗保健投资分析师,拥有多年的临床经验和工商管理硕士学位 [1] - 作者自2017年以来一直在Seeking Alpha上分享自己的分析,这是他最喜欢做的事情之一 [1] - 作者利用风险收益图表和折现现金流分析来突出投资机会和风险 [1] - 作者采用"哑铃策略",90%投资于国债和ETF等安全资产,10%投资于高增长股票,将风险管理放在首位 [1] - 由于市场相当有效,收益可能随机,作者从"超级预测"和"抗脆弱"中获得灵感,专注于概率预测和稳健策略,最小化风险同时最大化收益 [1] 免责声明 - 作者没有持有任何提及公司的股票、期权或类似衍生工具,也没有在未来72小时内进行任何此类持仓的计划 [2] - 本文是作者自己撰写的,表达的是自己的观点,作者没有从Seeking Alpha以外获得任何报酬 [2] - 作者与本文提及的任何公司都没有任何业务关系 [2] - 本文仅提供信息性内容,不应被视为对所述公司的详尽分析 [2] - 本文中的预测和意见基于作者的分析,反映了一种概率方法,而非绝对确定性 [2] - 尽管已尽力确保信息的准确性,但可能会出现无意的错误 [2] - 读者应独立核实信息并进行自己的研究,投资股票存在固有的波动性、风险和投机性 [2] - 在做出任何投资决策之前,读者都应该进行彻底的研究并评估自己的财务状况 [2] - 作者不对因使用或依赖本文内容而造成的任何财务损失负责 [2] Seeking Alpha免责声明 - 过去的业绩并不能保证未来的结果 [3] - 本网站不会就任何投资是否适合某位投资者提供任何建议或意见 [3] - 本网站上的任何观点或意见可能不代表Seeking Alpha整体的观点 [3] - Seeking Alpha不是持牌的证券交易商、经纪人或美国投资顾问或投资银行 [3] - 本网站的分析师是第三方作者,包括专业投资者和非专业投资者,可能未经任何机构或监管机构的认证 [3]

Exelixis (EXEL) shares ended the last trading session 8.6% higher at $28.50. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 4.5% loss over the past four weeks. Exelixis' shares gained on a favorable court ruling against MSN Laboratories for a generic product of lead drug Cabometyx (related to cabozantinib). The Delaware District Court ruled in Exelixis' favor, rejecting MSN's challenge to three listed patents rela ...

Exelixis, Inc. (EXEL) announced that the District Court of Delaware has ruled in its favor in the second patent litigation against MSN Laboratories. MSN is seeking approval for its generic product of Exelixis' cabozantinib. Details of EXEL's Patent Litigation Cabozantinib is marketed under the brand name Cabometyx for the treatment of renal cell carcinoma (RCC). EXEL has been involved in a lawsuit with MSN since 2019, when the latter submitted an abbreviated new drug application (ANDA) to the FDA requesting ...

文章核心观点 - 公司与制药巨头Merck签订临床开发合作协议,共同推进管线候选药物zanzalintinib的开发 [1][2][3] - 公司正在努力拓展其肿瘤药物组合和管线,除了其主打药物Cabometyx外,还有多个新药处于临床开发阶段 [4][5][6] 关于zanzalintinib的合作 - 公司将评估zanzalintinib与Merck的PD-1抑制剂Keytruda联合用于治疗头颈鳞状细胞癌的III期临床试验 [2] - 双方还将评估zanzalintinib与Merck的HIF2α抑制剂Welireg联合用于治疗肾细胞癌的I/II期和III期临床试验 [2][3] - Merck将为正在进行的STELLAR-305III期试验提供Keytruda,而公司将负责zanzalintinib的供应 [2][3] Cabometyx的进展 - Cabometyx与Bristol Myers的Opdivo联合用于一线治疗的表现出色,在肝细胞癌适应症上也保持了增长 [4] - 公司正在申请Cabometyx用于治疗胰腺神经内分泌肿瘤和胰外神经内分泌肿瘤的标签扩展,并计划提交联合Tecentriq用于转移性去势抵抗性前列腺癌的申请 [5] 管线拓展计划 - 公司决定终止XB002的开发,将资源重新分配到zanzalintinib的新的关键性试验、XL309的推进以及不断壮大的管线 [6] - 成功开发更多新药将有助于公司减少对Cabometyx的依赖,拓宽产品组合 [6]

文章核心观点 - 公司的主要药物Cabometyx在肾细胞癌和肝细胞癌适应症表现出色,有望进一步扩大适应症 [3][4] - 公司管线进展良好,包括下一代口服酪氨酸激酶抑制剂zanzalintinib和XL309等在研药物 [5][6] - 公司通过股票回购等方式积极回报股东 [7] 根据相关目录分别进行总结 公司业务表现 - 公司股价在过去3个月内上涨20.7%,超过行业6.3%的涨幅,也超过了大盘 [1][2] - Cabometyx是公司的主要收入来源,在肾细胞癌和肝细胞癌适应症表现出色 [3] - 公司正积极推进Cabometyx在胰腺神经内分泌瘤和胰外神经内分泌瘤适应症的拓展 [3] - 公司还计划提交Cabometyx联合Tecentriq用于转移性去势抵抗性前列腺癌的申请 [4] 管线进展 - 公司管线进展良好,包括下一代口服酪氨酸激酶抑制剂zanzalintinib和XL309等在研药物 [5] - 公司计划于2025年上半年启动zanzalintinib的III期临床试验,用于治疗胰腺神经内分泌瘤和胰外神经内分泌瘤 [5] - 公司还计划推进XL309和XB010的I期临床试验,但已决定终止XB002的开发 [5] - 新药物的成功开发将有助于公司减少对Cabometyx的依赖,丰富产品线 [6] 股东回报 - 公司通过股票回购方式积极回报股东,已完成2024年回购计划,累计回购2030万股 [7] - 公司董事会批准了额外的5亿美元股票回购计划,将持续至2025年底 [7]